Payment overview · 2025
General Payments
$114.24
6 reported records · 5 companies
Healthcare provider profile · identity verified
Todd Frederick Clarkson, DO
Allopathic & Osteopathic Physicians|General Practice · SEMINOLE, FL · NPI 1033210745
Verified facts
What the public records show
CMS Open Payments records show Todd Frederick Clarkson, DO received $114.24 in general payments during 2025 across 6 reported records.
GlaxoSmithKline, LLC. accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.09 | 36.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.42 | 18.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.67 | 16.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.08 | 14.9% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $14.98 | 13.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $114.24 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.09 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 514 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 472 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 121 |
| Alprazolam | Alprazolam | 313 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 97 |
| Omeprazole | Omeprazole | 291 | 83 |
| Metformin Hcl | Metformin Hcl | 283 | 80 |
| Losartan Potassium | Losartan Potassium | 246 | 79 |
| Simvastatin | Simvastatin | 238 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 61 |
| Trazodone Hcl | Trazodone Hcl | 195 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 57 |
| Gabapentin | Gabapentin | 189 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 45 |
| Tramadol Hcl | Tramadol Hcl | 154 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 33 |
| Glimepiride | Glimepiride | 131 | 35 |
| Temazepam | Temazepam | 131 | 20 |
| Meloxicam | Meloxicam | 121 | 34 |
| Lorazepam | Lorazepam | 96 | 19 |
| Eliquis | Apixaban | 93 | 24 |
| Azithromycin | Azithromycin | 91 | 72 |
| Allopurinol | Allopurinol | 87 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 26 |
| Methylprednisolone | Methylprednisolone | 86 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 17 |
| Diazepam | Diazepam | 79 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 25 |
| Sildenafil Citrate | Sildenafil Citrate | 76 | 13 |
| Atenolol | Atenolol | 75 | 19 |
| Furosemide | Furosemide | 75 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 11 |
| Ibuprofen | Ibuprofen | 73 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 22 |
| Famotidine | Famotidine | 64 | 19 |
| Finasteride | Finasteride | 64 | 20 |
| Baclofen | Baclofen | 61 | 14 |
| Ozempic | Semaglutide | 55 | suppressed |
| Clonazepam | Clonazepam | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 17 |
| Glipizide | Glipizide | 51 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 17 |
| Carvedilol | Carvedilol | 46 | 15 |
| Montelukast Sodium | Montelukast Sodium | 44 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Prednisone | Prednisone | 44 | 18 |
| Amoxicillin | Amoxicillin | 41 | 27 |
| Pregabalin | Pregabalin | 40 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 15 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 16 |
| Fluconazole | Fluconazole | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Estradiol | Estradiol | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 12 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $114.24 · 6 records | GlaxoSmithKline, LLC. | Dexcom G6 Transmitter, Extended Holter, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error